Central sleep apnea has a genetic component, but the relationship is more nuanced than a simple yes or no. In most adults, central sleep apnea develops from heart failure, opioid use, or high-altitude exposure rather than an inherited gene. However, the brainstem’s sensitivity to carbon dioxide, which is the core mechanism behind central sleep apnea, is partly determined by your genetics. And in one well-defined condition, a single gene mutation directly causes central sleep apnea from birth.
How Genetics Shape Breathing Control
Central sleep apnea happens when your brain temporarily stops sending signals to your breathing muscles during sleep. This is fundamentally different from obstructive sleep apnea, where the airway physically collapses. In central sleep apnea, the airway is open but the drive to breathe drops out.
Your brainstem constantly monitors carbon dioxide levels in your blood. When CO2 rises, the brainstem tells your diaphragm to breathe. How sensitive this system is varies from person to person, and twin studies provide the strongest evidence that genetic factors play a role. Research comparing identical and fraternal twins has shown that the depth of each breath during high-CO2 conditions is influenced by genetics, though breathing rate is not. In other words, your genes help set the “thermostat” for how aggressively your body responds to rising CO2, and a less sensitive thermostat makes central apnea events more likely.
Specific genes in both humans and mice have been identified that regulate baseline breathing patterns and the response to chemical changes in the blood. The RET gene, for example, is important for developing normal CO2 sensitivity. These genetic influences don’t guarantee central sleep apnea on their own, but they can make a person more vulnerable when combined with other risk factors like heart failure or sleeping at altitude.
The One Clear Genetic Cause: CCHS
Congenital central hypoventilation syndrome, or CCHS, is the condition where genetics directly and unmistakably cause central sleep apnea. It results from mutations in a gene called PHOX2B, which provides instructions for building a protein essential to nervous system development before birth. This protein helps nerve cells form and mature in the autonomic nervous system, the network that controls breathing, heart rate, blood pressure, and body temperature without conscious effort.
When PHOX2B is mutated, the autonomic nervous system doesn’t develop properly. Children with CCHS don’t respond normally to rising CO2 levels. During sleep, when conscious breathing effort drops away, their brains fail to maintain the automatic breathing signal. The result is dangerously shallow or absent breathing, primarily during sleep but sometimes while awake in severe cases.
More than 90 percent of CCHS cases come from new, spontaneous mutations rather than being passed down from a parent. In about 5 to 10 percent of cases, a child inherits the mutation from a parent who carries it only in their reproductive cells (sperm or eggs) and shows no symptoms themselves. This pattern, called germline mosaicism, means a parent can pass on the condition without knowing they carry it. CCHS is rare, affecting roughly 1 in 150,000 to 200,000 live births, but it illustrates how powerfully a single gene can control the breathing drive.
Living With CCHS
Children diagnosed with CCHS typically need mechanical ventilation during sleep for life. Some also use a device called a diaphragm pacer, which electrically stimulates the phrenic nerve to contract the diaphragm and produce a breath. This technology allows children to move freely during waking hours without being tethered to a ventilator. Patients in long-term pacing programs have used the devices for over a decade, and while complications like equipment failure or infection can occur, the approach significantly reduces the daily burden of the condition. Most patients receive mechanical ventilation at night and switch to phrenic nerve pacing during the day.
Related Conditions With Unclear Genetics
ROHHAD syndrome (rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation) is another rare childhood condition involving central hypoventilation, but its genetic basis remains unknown. Children with ROHHAD develop rapid weight gain, hormonal abnormalities, and progressively shallow breathing during sleep. About 40 percent also develop certain nerve-related tumors. Despite its clinical overlap with CCHS, testing consistently shows no PHOX2B mutations in ROHHAD patients, which means a different and still-unidentified mechanism is responsible.
New Genetic Leads From Large-Scale Studies
A large cross-tissue genetic study analyzing data from over 410,000 people identified 60 genes associated with sleep apnea susceptibility. Two genes stood out after rigorous validation. One, called GPD2, appears to reduce sleep apnea risk by regulating how cells produce energy. The other, L3MBTL2, may increase risk by disrupting DNA repair and cell cycle processes. These findings apply broadly to sleep apnea rather than central sleep apnea specifically, but they reinforce that genetic variation across many genes contributes to who develops breathing instability during sleep.
This kind of research is still in its early stages for central sleep apnea specifically. Unlike obstructive sleep apnea, which affects millions and generates large study populations, central sleep apnea is less common and harder to study at scale. The genetic architecture is likely polygenic for most adults, meaning dozens or hundreds of small genetic influences combine with environmental and medical factors to determine risk.
What This Means for Families
If you’re an adult with central sleep apnea, your condition is most likely driven by a medical factor like heart failure, a medication, or altitude rather than a gene you could pass to your children. That said, the sensitivity of your brainstem’s breathing center does have a heritable component, so a family history of any type of sleep apnea could signal shared vulnerability.
If your child has been diagnosed with central sleep apnea or unexplained hypoventilation, genetic testing for PHOX2B mutations is a standard part of the workup. A positive result confirms CCHS and has direct implications for treatment planning and for understanding whether siblings could be at risk. If PHOX2B testing is negative but symptoms persist, conditions like ROHHAD or other autonomic disorders may be considered.
For most people, central sleep apnea sits in a middle ground: not purely genetic, not purely environmental. Your genes set the baseline sensitivity of your breathing control system, and life circumstances determine whether that baseline ever becomes a clinical problem.